Keywords: bavituximab, yields, good, response, rates, ph, ib

Bavituximab yields good response rates in Ph Ib cancer trial

Article | 18 June 2007

California, USA-based Peregrine Pharmaceuticals has presented positive results from a Phase Ib trial of its oncology agent bavituximab, in combination ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Carboplatin

Paraplatin

Paclitaxel

Taxol

Go to drug listing